Navigation Links
Worm provides clues about preventing damage caused by low-oxygen during stroke, heart attack
Date:1/29/2009

Neurobiologists at Washington University School of Medicine in St. Louis have identified pathways that allow microscopic worms to survive in a low-oxygen, or hypoxic, environment.

They believe the finding could have implications for conditions such as stroke, heart attack and cancer. Sensitivity to low oxygen helps determine how damaging those medical conditions can be. The researchers report their findings in the Jan. 30 issue of the journal Science.

"In stroke and heart attack, cells die because they lack oxygen," explains principal investigator C. Michael Crowder, M.D., Ph.D. "In cancer, the opposite is true. Cancer cells are hypoxia-resistant in many cases, and their potential to spread throughout the body tends to correlate with their degree of hypoxia resistance."

Crowder says it may be possible to develop more effective therapies for stroke and heart attack, on one hand, and cancer, on the other, when scientists better understand how cells protect themselves from oxygen deprivation. In the case of stroke and heart attack, therapies would involve making healthy cells resistant to hypoxia. Cancer therapies might work more effectively if it were possible to make hypoxia-resistant cells more vulnerable to low oxygen levels.

In new experiments, Crowder's team manipulated genes in the worm Caenorhabditis elegans to alter the organism's sensitivity to a low-oxygen environment. They did that by identifying a gene that controls the translation of genetic information into specific proteins. Mutant copies of the gene cut translation rates in half, which conferred 100% survival to the animals compared to 100% death in non-mutant worms.

Crowder says that inhibiting translation likely protects cells from hypoxia by reducing energy consumption because making proteins consumes a lot of energy. The researchers were surprised by the degree of resistance to hypoxia when the translation rate was cut. They wanted to find out whether increasing hypoxia resistance was explained only by the fact that the cells were using less energy.

In a second experiment, the researchers introduced another mutation into the worms to evaluate its effect on the original mutation. The second mutation affects a process known as protein folding.

"In some cells, hypoxia has been shown to generate unfolded proteins," says Crowder, the Dr. Seymour and Rose T. Brown Professor in Anesthesiology and professor of developmental biology. "So then you have this load of unfolded proteins that may be toxic and promote cell death from hypoxia. We wondered whether suppressing translation in the cell might make it resistant to hypoxia by reducing the load of unfolded proteins, and that's what we saw."

Folding is important in allowing proteins to function properly. Every protein has shapes and pockets and active sites that bind to other proteins and perform various functions. If a particular protein doesn't "fold" into the proper shape, it can't do its job. It's not clear why that might be toxic, but this study suggests fewer improperly folded proteins make exposure to low oxygen less toxic.

Connecting these discoveries to potential stroke and heart attack therapies will involve several steps. First, Crowder plans to move beyond C. elegans to see whether these techniques also will protect neurons in mammals.

"If that happens, then I think there's hope that, eventually, we could target this process for therapy," Crowder says. "At this point in time, I think we're really just scratching the surface of the basic mechanisms of what controls hypoxic injury. It may be that protein translation doesn't ultimately end up being the answer, but maybe it will lead us to an answer. It already has led us to this unfolded protein response that seems to have potential as a therapy."

The challenge in treating stroke is that most cells in the brain continue to get plenty of oxygen. Only the part of the brain directly affected by the stroke becomes hypoxic. So Crowder says potential therapies need to protect brain cells affected by hypoxia without harming other cells that continue to experience normal oxygen levels. Targeting the unfolded protein response is attractive because, in theory, therapies would not bother cells with adequate oxygen but would react with the improper protein folding that occurs in cells not getting enough oxygen. Whether such a strategy will work is unknown.

"Many people have thought they made very promising inroads into stroke therapy over the last 50 years, and none of those treatments have been good enough," Crowder says. "We have no illusions that finding ways to reduce cell death from hypoxia will be easy. But using this approach of randomly mutating genes and seeing what happens helped us to find this unfolded protein response. It works in the worm, so now let's see what happens in mammals."


'/>"/>

Contact: Jim Dryden
jdryden@wustl.edu
314-286-0110
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Young Innovations, Inc. Provides Fourth Quarter Conference Call Details
2. Air Methods Provides 4th Quarter Update
3. Providence Service Corporation Provides The Center on Budget and Policy Priorities Preliminary Analysis of Potential Medicaid Assistance for States in the House Economic Recovery Package
4. IncentOne Provides Incentive Solution to CIGNA
5. Quest Diagnostics Reports Growth in Revenue and Earnings for Fourth Quarter 2008 and Provides 2009 Guidance
6. EliteMeetings.com Announces Commission-Free Policy Comprehensive Search and RFP Engine Now Provides Net Rates for Groups
7. The Doctors Company Provides Tips for Physicians to Minimize Risk While Practicing Medicine by Phone or E-mail
8. Wainwright Bank Provides $10.6 Million to Harbor Health Services, Inc.
9. Providence Service Corporation Provides Update on Potential Medicaid
10. Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008
11. China Sky One Medical, Inc. Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: